Can-Fite BioPharma Ltd. (CANF) stock
Close on Nov 11, 2026Market cap $2.03MP/E –Yield –
Can-Fite BioPharma Ltd. saw revenue fall 39.9% to $405.00K over fiscal 2025. Free cash flow was -$8.95M. At the latest close the market valued the company at $2.03M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $2.03M
- P/E ratio
- –
- Price to sales
- 5.01
- Price to book
- 0.42
- Dividend yield
- –
- Free cash flow yield
- -441.09%
Fundamentals
- Revenue
- $405.00K
- Net income
- -$9.83M
- EPS, diluted
- -$5.97
- Free cash flow
- -$8.95M
Trading
- Previous close
- $1.66
- Open
- $1.64
- Day's range
- $1.55 – $1.64
- Volume
- 22,233
- Average volume (20 days)
- 68,507
- Beta (5 years)
- 1.12
- 52-week range
- $1.50 – $12.30
- RSI (14 days)
- 29.3
- Volatility (1 year)
- 104.1%
- Relative volume
- 0.08×
- WACC
- 10.5%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CANF | S&P 500 | Difference | CANF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.4% | -2.4% | −16.0 pts | ||
| 3 months | -53.2% | -1.2% | −52.0 pts | ||
| Year to date | -61.3% | +12.3% | −73.5 pts | ||
| 1 year | -80.4% | +12.4% | −92.9 pts | ||
| 3 years | -96.0% | +78.8% | −174.8 pts | -65.8% | +21.4% |
| 5 years | -99.4% | +75.2% | −174.6 pts | -64.6% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -56.9% | +15.2% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Can-Fite BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Can-Fite BioPharma
Pharmaceutical Preparations
Can-Fite BioPharma Ltd. is an advanced clinical-stage biopharmaceutical company that develops orally bioavailable small molecule therapeutic products. Its research and development efforts focus on treatments for cancer, liver diseases, and inflammatory conditions. The company's technology platform targets the Gi protein-associated A3 adenosine receptor, which displays elevated expression in pathological body cells compared to normal cells. Can-Fite's pipeline includes synthetic, highly specific agonists and allosteric modulators, prominently featuring drug candidates Piclidenoson, Namodenoson, and CF602. The company interacts with commercial partners and biopharmaceutical collaborators, including Ewopharma, Gebro Holding, Chong Kun Dang Pharmaceuticals, Cipher Pharmaceuticals, and Vetbiolix, through out-licensing and development agreements.
Company profile, executives and historyCan-Fite BioPharma stock: common questions
What is Can-Fite BioPharma's stock price?
CANF closed at $1.55 on Nov 11, 2026, down 6.63% on the day. Over the past 52 weeks it traded between $1.50 and $12.30.
What is Can-Fite BioPharma's market cap?
Can-Fite BioPharma was worth $2.03M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CANF's P/E ratio?
Can-Fite BioPharma lost money over fiscal 2025 (diluted EPS -$5.97), so it has no meaningful P/E ratio.
How much revenue does Can-Fite BioPharma make?
Can-Fite BioPharma reported revenue of $405.00K for fiscal 2025, down 39.9% from a year earlier.
Does Can-Fite BioPharma pay a dividend?
No. Can-Fite BioPharma has not paid a cash dividend over the last twelve months.
How has CANF stock performed over the past year?
Including dividends, CANF returned -80.4% over the past year, against +12.4% for the S&P 500.
Who are Can-Fite BioPharma's competitors?
Companies most similar to Can-Fite BioPharma by business, industry and size include XTLB, LIPO, SCNX, RLYB, RDHL.
See a number that looks wrong?